The HeartMate II™ Continuous-Flow Left Ventricular Assist System

2019 ◽  
pp. 70-77
Author(s):  
David J. Farrar
Keyword(s):  
Left Ventricular ◽  
Circulatory Support ◽  
Left Ventricular Assist System ◽  
Heartmate Ii ◽  
Ventricular Assist ◽  
Pump Speed ◽  
System P ◽  
Left Ventricular Assist ◽  
Mechanical Circulatory Support Device ◽  
End Stage

The HeartMate II™ Left Ventricular Assist System has been implanted in more than 26,000 patients and is the most widely used and studied durable mechanical circulatory support device in patients with advanced heart failure. The device is intended for use as bridge to transplantation in candidates at risk of imminent death from non-reversible left ventricular (LV) failure and for destination therapy for use in patients with end-stage LV failure. This chapter describes each component of the system, the mechanisms of the pump itself, the physiology of blood flow under different pump speeds and pressure gradients, and ways to prevent pump thrombus. In addition, the functions and interface of the System Controller and System Monitor are detailed, including the settings displayed on the monitor and the type of alarms provided, as well as their appearance on the interface. The chapter closes with a discussion of how a ramped-speed study using echocardiography and hemodynamic assessment can identify the pump speed that provides the desired level of cardiac support for each patient.

The Abbott HeartMate 3™ Left Ventricular Assist System

2019 ◽  
pp. 78-83
Author(s):  
Kevin Bourque ◽  
John B. O’Connell
Keyword(s):  
Magnetic Levitation ◽  
Left Ventricular ◽  
Circulatory Support ◽  
Left Ventricular Assist System ◽  
Ventricular Assist ◽  
System P ◽  
Pump Thrombosis ◽  
Left Ventricular Assist ◽  
Mechanical Circulatory Support Devices ◽  
Support Devices

Mechanical circulatory support devices are increasingly used to treat chronic, advanced heart failure. In the Abbott HeartMate 3™ left ventricular assist system (HM3), a new magnetic levitation pump improves hemocompatibility and thus addresses the prominent morbidities associated with these devices, such as pump thrombosis, stroke, and bleeding. In the multicenter MOMENTUM 3 clinical trial of 366 patients, the primary endpoint—survival without disabling stroke or pump replacement—was 77.9% in the HM3 group (n = 190) and 56.4% in the HeartMate II™ Left Ventricular Assist System group (HMII; n = 176; P <0.001). Suspected or confirmed pump thrombosis occurred in two patients (1.1%) in the HM3 group and in 27 patients (15.7%) in the HMII group (P <0.001). Also at 2 years, 22 strokes occurred in 19 patients (10.1%) with the HM3 and 43 strokes occurred in 33 patients (19.2%) with the HMII (P = 0.02), indicating that the HM3 provides important improvements in care.

Application of Wearable Novacor Left Ventricular Assist System for Patients with End-Stage Cardiomyopathy: Osaka Experience

1998 ◽  
pp. 210-216 ◽  
Author(s):  
Takafumi Masai ◽  
Keishi Kadoba ◽  
Yuji Miyamoto ◽  
Yoshiki Sawa ◽  
Hajime Ichikawa ◽  
...  
Keyword(s):  
Left Ventricular ◽  
Left Ventricular Assist System ◽  
Ventricular Assist ◽  
Left Ventricular Assist ◽  
End Stage

Hemodynamics in Patients with a HeartMate II Left Ventricular Assist Device Are Altered with Acute Pump Speed Changes

2007 ◽  
Vol 13 (6) ◽  
pp. S112 ◽  
Author(s):  
Stuart D. Russell ◽  
MaryAnn Albaugh ◽  
Susan Ullrich ◽  
Heather M. Richardson ◽  
Jessica L. Dossa ◽  
...  
Keyword(s):  
Left Ventricular Assist Device ◽  
Ventricular Assist Device ◽  
Left Ventricular ◽  
Assist Device ◽  
Heartmate Ii ◽  
Ventricular Assist ◽  
Pump Speed ◽  
Left Ventricular Assist

scholarly journals Experience with the HeartMate II Left Ventricular Assist Device in Patients Older than 60 Years

2019 ◽  
Vol 22 (2) ◽  
pp. E124-E130 ◽  
Author(s):  
Zumrut T. Demirozu ◽  
Andre Critsinelis ◽  
William E. Cohn ◽  
Rajko Radovancevic ◽  
Jonathan Ho ◽  
...  
Keyword(s):  
Heart Transplantation ◽  
Left Ventricular Assist Device ◽  
Ventricular Assist Device ◽  
Left Ventricular ◽  
Advanced Age ◽  
Circulatory Support ◽  
Assist Device ◽  
Heartmate Ii ◽  
Ventricular Assist ◽  
Left Ventricular Assist

Background: Advanced age is a relative contraindication for heart transplantation, but no age cutoff has been defined for patients receiving mechanical circulatory support. Methods: Between November 1, 2003 and November 1, 2012, we implanted the HeartMate II (HMII) left ventricular assist device (LVAD) in 319 patients. One hundred seven patients (89 men, 18 women) were over 60 years old (mean, 66 ± 4 years; range, 61-78 years) and received the HMII as a bridge to transplantation (n = 45) or as destination therapy (n = 62). We evaluated their experience by performing a retrospective analysis. Results: Seventy-two patients had ischemic cardiomyopathy, and 34 had idiopathic cardiomyopathy. Three patients (2.8%) already had a HeartMate XVE LVAD; 54 (50.5%) were receiving intra-aortic balloon pump support; 52 (48.6%) had undergone a previous cardiac procedure; and 9 (8.4%) had received renal replacement therapy (RRT) (continuous venovenous hemofiltration, hemodialysis, or both) before HMII implantation. The median duration of HMII support was 313 days (range, 1-3339 days). After device implantation, 36 patients (33.6%) had gastrointestinal bleeding, 24 (23%) required RRT, 18 (17.5%) had ventricular arrhythmias, and 24 (22.4%) had LVAD-related infections, and 9 (8.4%) had right ventricular failure requiring mechanical support, and 28 (26.2%) had neurologic complications. The actual survival rate was 69% at 6 months, 63% at 1 year, and 54% at 2 years. Eighty-one patients died; 9 are still receiving HMII support; and 17 are alive after heart transplantation. Conclusions: Older patients can benefit from LVAD therapy, and advanced age should not preclude LVAD implantation.

Novacor Left Ventricular Assist System

1991 ◽  
Vol 2 (3) ◽  
pp. 575-586 ◽  
Author(s):  
Julie A. Shinn
Keyword(s):  
Clinical Investigation ◽  
Left Ventricular ◽  
Circulatory Support ◽  
Patient Support ◽  
Left Ventricular Assist System ◽  
Ventricular Assist ◽  
Left Ventricular Assist ◽  
Upper Abdominal ◽  
Abdominal Quadrant

Clinical investigation of the Novacor ventricular assist system has been ongoing since 1984. Major successes have been achieved using the device as a bridge to heart transplant. This system uses an electrically driven, pulsatile pump implanted in the left upper abdominal quadrant. The system has demonstrated the ability to provide long-term patient support, a feature that allows patients to become mobile and active once recovered from their initial heart failure. By the time of transplant, nutrition is restored, activity tolerance is improved, and most patients require no inotropic support. The system allows patients to recover from cardiogenic shock by providing total systemic circulatory support

HeartMate II left ventricular assist system: from concept to first clinical use

2001 ◽  
Vol 71 (3) ◽  
pp. S116-S120 ◽  
Author(s):  
Bartley P Griffith ◽  
Robert L Kormos ◽  
Harvey S Borovetz ◽  
Kenneth Litwak ◽  
James F Antaki ◽  
...  
Keyword(s):  
Left Ventricular ◽  
Clinical Use ◽  
Left Ventricular Assist System ◽  
Heartmate Ii ◽  
Ventricular Assist ◽  
Left Ventricular Assist
Sign in / Sign up

Export Citation Format

Share Document